News
-
-
-
-
-
-
PRESS RELEASE
Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
Applied DNA Sciences reschedules Investor Update call to February 13, 2025, coinciding with Q1 fiscal 2025 results release due to National Day of Mourning. Company develops PCR-based technologies -
-
-
PRESS RELEASE
Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
Regulatory approval for Phase I clinical trial of CD123-specific autologous CAR T-cell therapy by UHKT showcases Linea DNA as a rapid and cost-efficient manufacturing solution for AML treatment -